Literature DB >> 27960197

Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy.

Margaret A Honein1, April L Dawson1, Emily E Petersen1, Abbey M Jones1, Ellen H Lee2, Mahsa M Yazdy3, Nina Ahmad4, Jennifer Macdonald5, Nicole Evert6, Andrea Bingham7, Sascha R Ellington1, Carrie K Shapiro-Mendoza1, Titilope Oduyebo1, Anne D Fine2, Catherine M Brown3, Jamie N Sommer4, Jyoti Gupta5, Philip Cavicchia7, Sally Slavinski2, Jennifer L White4, S Michele Owen1, Lyle R Petersen1, Coleen Boyle1, Dana Meaney-Delman1, Denise J Jamieson1.   

Abstract

Importance: Understanding the risk of birth defects associated with Zika virus infection during pregnancy may help guide communication, prevention, and planning efforts. In the absence of Zika virus, microcephaly occurs in approximately 7 per 10 000 live births. Objective: To estimate the preliminary proportion of fetuses or infants with birth defects after maternal Zika virus infection by trimester of infection and maternal symptoms. Design, Setting, and Participants: Completed pregnancies with maternal, fetal, or infant laboratory evidence of possible recent Zika virus infection and outcomes reported in the continental United States and Hawaii from January 15 to September 22, 2016, in the US Zika Pregnancy Registry, a collaboration between the CDC and state and local health departments. Exposures: Laboratory evidence of possible recent Zika virus infection in a maternal, placental, fetal, or infant sample. Main Outcomes and Measures: Birth defects potentially Zika associated: brain abnormalities with or without microcephaly, neural tube defects and other early brain malformations, eye abnormalities, and other central nervous system consequences.
Results: Among 442 completed pregnancies in women (median age, 28 years; range, 15-50 years) with laboratory evidence of possible recent Zika virus infection, birth defects potentially related to Zika virus were identified in 26 (6%; 95% CI, 4%-8%) fetuses or infants. There were 21 infants with birth defects among 395 live births and 5 fetuses with birth defects among 47 pregnancy losses. Birth defects were reported for 16 of 271 (6%; 95% CI, 4%-9%) pregnant asymptomatic women and 10 of 167 (6%; 95% CI, 3%-11%) symptomatic pregnant women. Of the 26 affected fetuses or infants, 4 had microcephaly and no reported neuroimaging, 14 had microcephaly and brain abnormalities, and 4 had brain abnormalities without microcephaly; reported brain abnormalities included intracranial calcifications, corpus callosum abnormalities, abnormal cortical formation, cerebral atrophy, ventriculomegaly, hydrocephaly, and cerebellar abnormalities. Infants with microcephaly (18/442) represent 4% of completed pregnancies. Birth defects were reported in 9 of 85 (11%; 95% CI, 6%-19%) completed pregnancies with maternal symptoms or exposure exclusively in the first trimester (or first trimester and periconceptional period), with no reports of birth defects among fetuses or infants with prenatal exposure to Zika virus infection only in the second or third trimesters. Conclusions and Relevance: Among pregnant women in the United States with completed pregnancies and laboratory evidence of possible recent Zika infection, 6% of fetuses or infants had evidence of Zika-associated birth defects, primarily brain abnormalities and microcephaly, whereas among women with first-trimester Zika infection, 11% of fetuses or infants had evidence of Zika-associated birth defects. These findings support the importance of screening pregnant women for Zika virus exposure.

Entities:  

Mesh:

Year:  2017        PMID: 27960197     DOI: 10.1001/jama.2016.19006

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  182 in total

1.  Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies.

Authors:  Ai-Ris Y Collier; Erica N Borducchi; Abishek Chandrashekar; Edward Moseley; Lauren Peter; Nicholas S Teodoro; Joseph Nkolola; Peter Abbink; Dan H Barouch
Journal:  Am J Reprod Immunol       Date:  2020-07-01       Impact factor: 3.886

Review 2.  Maternal-Fetal Transmission of Zika Virus: Routes and Signals for Infection.

Authors:  Bin Cao; Michael S Diamond; Indira U Mysorekar
Journal:  J Interferon Cytokine Res       Date:  2017-04-12       Impact factor: 2.607

3.  Responsible Care in the Face of Shifting Recommendations and Imperfect Diagnostics for Zika Virus.

Authors:  Ilona Telefus Goldfarb; Elana Jaffe; Anne Drapkin Lyerly
Journal:  JAMA       Date:  2017-12-05       Impact factor: 56.272

4.  Refinement and Analysis of the Mature Zika Virus Cryo-EM Structure at 3.1 Å Resolution.

Authors:  Madhumati Sevvana; Feng Long; Andrew S Miller; Thomas Klose; Geeta Buda; Lei Sun; Richard J Kuhn; Michael G Rossmann
Journal:  Structure       Date:  2018-06-26       Impact factor: 5.006

Review 5.  Zika virus: a public health perspective.

Authors:  Nahida Chakhtoura; Rohan Hazra; Catherine Y Spong
Journal:  Curr Opin Obstet Gynecol       Date:  2018-04       Impact factor: 1.927

Review 6.  Impact of Zika virus for infertility specialists: current literature, guidelines, and resources.

Authors:  Jamie P Dubaut; Nelson I Agudelo Higuita; Alexander M Quaas
Journal:  J Assist Reprod Genet       Date:  2017-07-07       Impact factor: 3.412

7.  Zika virus, a novel mosquito-borne congenital virus infection.

Authors:  J David Beckham
Journal:  J Neurovirol       Date:  2017-04-20       Impact factor: 2.643

8.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Authors:  Davide F Robbiani; Leonia Bozzacco; Jennifer R Keeffe; Ricardo Khouri; Priscilla C Olsen; Anna Gazumyan; Dennis Schaefer-Babajew; Santiago Avila-Rios; Lilian Nogueira; Roshni Patel; Stephanie A Azzopardi; Lion F K Uhl; Mohsan Saeed; Edgar E Sevilla-Reyes; Marianna Agudelo; Kai-Hui Yao; Jovana Golijanin; Harry B Gristick; Yu E Lee; Arlene Hurley; Marina Caskey; Joy Pai; Thiago Oliveira; Elsio A Wunder; Gielson Sacramento; Nivison Nery; Cibele Orge; Federico Costa; Mitermayer G Reis; Neena M Thomas; Thomas Eisenreich; Daniel M Weinberger; Antonio R P de Almeida; Anthony P West; Charles M Rice; Pamela J Bjorkman; Gustavo Reyes-Teran; Albert I Ko; Margaret R MacDonald; Michel C Nussenzweig
Journal:  Cell       Date:  2017-05-04       Impact factor: 41.582

Review 9.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

Review 10.  Ribosomal biogenesis as an emerging target of neurodevelopmental pathologies.

Authors:  Michal Hetman; Lukasz P Slomnicki
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.